Physician profile
April E Yuki
NPI 1437318896
$2,322.10
in general payments reported to CMS, 2019-2025
21 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2021: $82.33 · 2022: $486 · 2023: $342 · 2024: $277 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.12 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.78 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Livanova USA, INC. | $465.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $166.12 | 2022 | |
| Mdd US Operations, LLC | $97.95 | 2024 | Apokyn |
| Allergan, INC. | $97.66 | 2019-2022 | |
| Ucb, INC. | $94.59 | 2025 | Fintepla, Nayzilam |
| Kyowa Kirin, INC. | $91.56 | 2021-2024 | Nourianz |
| Cala Health, INC. | $79.75 | 2023 | Cala Trio |
| Sk Life Science, INC. | $73.96 | 2022-2025 | |
| Revance Therapeutics, INC. | $52.58 | 2024 | Daxxify |
| Amneal Pharmaceuticals LLC | $52.41 | 2025 | Crexont |
| Pfizer INC. | $45.98 | 2025 | |
| Vanda Pharmaceuticals INC. | $45.53 | 2025 | Ponvory |
| Biogen, INC. | $39.63 | 2021-2025 | Tysabri |
| Takeda Pharmaceuticals U.S.A., INC. | $30.86 | 2025 | Hyqvia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $30.81 | 2022 | |
| Eisai INC. | $27.67 | 2025 | |
| Grt US Holding, INC. | $22.78 | 2022 | |
| Acorda Therapeutics, INC | $20.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.22 | 2019 | |
| Lilly USA, LLC | $13.81 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Yuki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.